Get the Stockscreener App
71.10
0.45%
0.0686
Tarsus Pharmaceuticals Inc stock is traded at $71.10, with a volume of 21,100.
It is up +0.45% in the last 24 hours and down -13.13% over the past month.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
See More
Previous Close:
$71.03
Open:
$71.05
24h Volume:
21,100
Relative Volume:
0.04
Market Cap:
$3.02B
Revenue:
$17.39M
Net Income/Loss:
$-135.89M
P/E Ratio:
-15.32
EPS:
-4.64
Net Cash Flow:
$-123.00M
1W Performance:
+0.30%
1M Performance:
-13.13%
6M Performance:
+69.00%
1Y Performance:
+45.26%
1-Day Range:
$71.01
$72.10
1-Week Range:
$69.46
$73.82
52-Week Range:
$38.51
$85.25
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
Name
Tarsus Pharmaceuticals Inc
Sector
Industry
Phone
(949) 409-9820
Address
15440 LAGUNA CANYON ROAD, IRVINE
Compare TARS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TARS
Tarsus Pharmaceuticals Inc
|
71.13 | 3.02B | 17.39M | -135.89M | -123.00M | -4.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.58 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.82 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
830.94 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
363.26 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
341.94 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Overweight |
| Nov-20-25 | Initiated | Mizuho | Outperform |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-27-25 | Resumed | H.C. Wainwright | Buy |
| Nov-20-23 | Initiated | Goldman | Neutral |
| Jul-18-23 | Initiated | William Blair | Outperform |
| May-18-23 | Initiated | Guggenheim | Buy |
| Aug-01-22 | Initiated | Barclays | Overweight |
| Dec-21-21 | Initiated | H.C. Wainwright | Buy |
| Nov-23-21 | Initiated | Oppenheimer | Outperform |
| Nov-10-20 | Initiated | BofA Securities | Buy |
| Nov-10-20 | Initiated | Jefferies | Buy |
| Nov-10-20 | Initiated | Ladenburg Thalmann | Buy |
| Nov-10-20 | Initiated | Raymond James | Strong Buy |
View All
Tarsus Pharmaceuticals Inc Stock (TARS) Latest News
Portfolio Update: Does Tarsus Pharmaceuticals Inc have declining or rising EPSQuarterly Earnings Report & Long-Term Growth Plans - baoquankhu1.vn
Relative Strength Alert For Tarsus Pharmaceuticals - Nasdaq
Does Tarsus Pharmaceuticals (NASDAQ:TARS) Have A Healthy Balance Sheet? - simplywall.st
While shareholders of Tarsus Pharmaceuticals (NASDAQ:TARS) are in the black over 3 years, those who bought a week ago aren't so fortunate - Yahoo Finance
Understanding Momentum Shifts in (TARS) - Stock Traders Daily
BMRN or TARS: Which Is the Better Value Stock Right Now? - Yahoo Finance
Aug PostEarnings: Why Tarsus Pharmaceuticals Inc. stock could rally in 20252025 Bull vs Bear & AI Based Trade Execution Alerts - Bộ Nội Vụ
Tarsus Pharmaceuticals, Inc. Publishes Corporate Presentation on Eye Care Innovations - TradingView — Track All Markets
What analyst consensus says on Tarsus Pharmaceuticals Inc. stockStop Loss & Smart Allocation Stock Tips - Улправда
Why Tarsus Pharmaceuticals Inc. stock is trending among retail tradersPortfolio Value Report & Real-Time Stock Entry Alerts - Улправда
Growth Recap: Why Tarsus Pharmaceuticals Inc. stock is trending among retail tradersMarket Activity Summary & Free Long-Term Investment Growth Plans - Улправда
Will Tarsus Pharmaceuticals Inc. stock outperform tech sector in 2025Portfolio Gains Summary & Free Real-Time Volume Trigger Notifications - Улправда
Tarsus Pharmaceuticals (NASDAQ:TARS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway - 富途牛牛
Insider Sell Alert: Dianne Whitfield Sells 15,565 Shares of Tarsus Pharmaceuticals Inc (TARS) - GuruFocus
Avoiding Lag: Real-Time Signals in (TARS) Movement - Stock Traders Daily
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Tarsus Pharmaceuticals (NASDAQ:TARS) CEO Bobak Azamian Sells 6,000 Shares - MarketBeat
Tarsus Pharmaceuticals Insider Sold Shares Worth $495,089, According to a Recent SEC Filing - MarketScreener
Tarsus Pharmaceuticals (TARS) Investor Outlook: Strong Buy Ratings and Promising Revenue Growth in Biotech - DirectorsTalk Interviews
Will Tarsus Pharmaceuticals Inc. stock split attract more investorsDividend Cut Warnings & Low Risk Investment Plans - bollywoodhelpline.com
Tarsus to Participate at the Bank of America 2023 Healthcare Conference - 富途牛牛
240,020 Shares in Tarsus Pharmaceuticals, Inc. $TARS Purchased by Capricorn Fund Managers Ltd - MarketBeat
Tarsus Pharmaceuticals Earnings Notes - Trefis
Market Sentiment Around Loss-Making Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - simplywall.st
Will Tarsus Pharmaceuticals Inc. stock see PE expansionTake Profit Strategies & Free Hedging Tactics for Volatile Markets - Bollywood Helpline
Tarsus Pharmaceuticals (TARS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Technical Reactions to TARS Trends in Macro Strategies - Stock Traders Daily
Why Tarsus Pharmaceuticals Inc. stock could rally in 2025July 2025 Opening Moves & Weekly Breakout Watchlists - Улправда
Can Tarsus Pharmaceuticals Inc. stock double in next 5 yearsJuly 2025 Retail & AI Enhanced Trading Signals - Улправда
Can Tarsus Pharmaceuticals Inc. stock hit record highs againJuly 2025 Trade Ideas & AI Driven Price Predictions - DonanımHaber
Why analysts upgrade Tarsus Pharmaceuticals Inc. stock2025 Technical Overview & Fast Gaining Stock Reports - Улправда
Insider Sell: Dianne Whitfield Sells 7,397 Shares of Tarsus Phar - GuruFocus
Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Dianne Whitfield Sells 7,397 Shares - MarketBeat
Tarsus Pharmaceuticals Insider Sold Shares Worth $592,500, According to a Recent SEC Filing - marketscreener.com
Tarsus Pharmaceuticals (TARS) COO discloses stock gifts and 79,183-share stake - Stock Titan
Assenagon Asset Management S.A. Has $74.17 Million Stock Holdings in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Officer Whitfield Files To Sell 7,397 Of Tarsus Pharmaceuticals Inc [TARS] - TradingView — Track All Markets
Squarepoint Ops LLC Boosts Position in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
TFG Asset Management GP Ltd Grows Stake in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Trading the Move, Not the Narrative: (TARS) Edition - Stock Traders Daily
Tarsus Pharmaceuticals (NASDAQ:TARS) Upgraded at Barclays - MarketBeat
Tarsus Pharmaceuticals chief medical officer talks AI in eye care - Healthcare Brew
Barclays Initiates Coverage on Tarsus Pharmaceuticals (TARS) wit - GuruFocus
Jump Financial LLC Purchases 188,317 Shares of Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Norges Bank Acquires Shares of 471,354 Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Tarsus Pharmaceuticals (NASDAQ:TARS) Sets New 12-Month HighHere's What Happened - MarketBeat
Tarsus Pharmaceuticals stock hits all-time high at 83.67 USD - Investing.com
Tarsus Pharmaceuticals stock hits all-time high at 83.67 USD By Investing.com - Investing.com Australia
Tarsus Pharmaceuticals Leads Six-Month Stock Performance with 85.5% Return - Markets Mojo
Quantbot Technologies LP Purchases 24,319 Shares of Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Tarsus Pharmaceuticals Inc Stock (TARS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.22%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):